Greg Duncan, Virios Therapeutics CEO
Blaming Covid-19 for initial data issues, antiviral biotech reports PhIIb fibromyalgia fail — shares tank
Close to two years after making the jump to Nasdaq and raising $30 million via IPO, Virios Therapeutics has failed on a mid-stage study and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
